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Abstract
Immunization coverage with oral poliovirus vaccines in Sri Lanka consistently reaches >90%. We 
evaluated seroprevalence of poliovirus neutralizing antibodies in 400 randomly selected children 
aged 9–11 months, 3–4 years, 7–9 years and 15 years, from three districts of Sri Lanka. 
Seroprevalence of antibodies against types 1 and 2 was above 95% in all age groups; for type 3 it 
was 95%, 90%, 77% and 75% in the respective age groups. The declining seroprevalence with age 
for serotype 3 is likely not correlated with protection. This survey provides baseline data prior to 
introduction of inactivated poliovirus vaccine in Sri Lanka.
Introduction
With polio eradication making rapid progress, only three countries remain in 2014 which 
have never eradicated wild poliovirus (Afghanistan, Nigeria, and Pakistan) [1]. In this 
context, a high priority is assigned to preparations for the post-eradication era. The key 
policy changes described in the Polio Eradication & Endgame Strategic Plan 2013–2018 [2] 
are global cessation of the type-2 component of oral poliovirus vaccine (OPV) (meaning 
switch from trivalent OPV [tOPV] to bivalent OPV [bOPV]); and the global introduction of 
at least one dose of inactivated poliovirus vaccine (IPV) into every country’s routine 
immunization schedule. The strategy will allow for cessation of circulation and emergence 
of vaccine-derived poliovirus type 2 (VDPV2) while the last endemic foci of wild poliovirus 
are cleared [3].
The last case of poliomyelitis in Sri Lanka was reported in 1993 [4]. The routine 
immunization program in Sri Lanka is considered to be well performing and includes five 
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doses of OPV administered at 2, 4, and 6 months of age as a primary series followed by 
revaccinations at 18 months and 5 years of age. The vaccination coverage with the third 
OPV dose has consistently exceeded 95% nationwide with unimportant sub-national 
variations [5]. Supplementary immunization activities (SIAs) have been conducted to 
address known population immunity gaps from 1995–2003 but there have been no polio 
vaccination campaigns since 2003.
Sri Lanka plans to introduce one dose of IPV into its routine immunization schedule in 
2015. Following the recommendation of the Strategic Advisory Group of Experts, IPV will 
be co-administered with a dose of OPV after 14 weeks of age [6]. The switch from tOPV to 
bOPV is planned for April 2016.
This study provides baseline data on seroprevalence of polio neutralizing antibodies in 
targeted age groups in Sri Lanka in anticipation of the IPV introduction and tOPV to bOPV 
switch.
Methods
We performed a cross-sectional community-based survey in three districts of Sri Lanka: 
Colombo, Badulla and Killinochchi. The study area represented lower socio-economic strata 
of Sri Lankan society. Children in four age groups were selected: 9–11 months, 3–4 years, 
7–9 years and 15 years of age.
The subjects were randomly selected from field-level health registers kept with the Medical 
Officers of Health. Parents of eligible children were approached during regular visits of 
Public Health Midwives, consented and enrolled. On the same day, the subjects were 
transported to the nearest health center where one 1ml blood sample was collected and a 
short questionnaire administered.
The blood specimens were allowed to clot. Sera were separated and transported to Colombo, 
where they were stored at −20° C until shipment to the Centers for Disease Control and 
Prevention (CDC) in Atlanta, USA. The sera were tested for the presence of poliovirus 
neutralizing antibodies using standard microneutralization assays [7, 8]. Seropositivity was 
defined as reciprocal titers of poliovirus neutralizing antibodies ≥8.
Vaccination history of the enrolled children was recorded from vaccination cards when 
available; otherwise, the history was obtained through parental recall.
A sample size of 100 children in each age group (to a total of 400 children) was calculated 
to be sufficient to detect, at the 95% confidence level, a seroprevalence point estimate with a 
precision of approximately +/− 5% assuming ≥ 90% seroprevalence.
Ethical clearance was obtained by the Ethical Committees of the Ministry of Health, Sri 
Lanka and of the World Health Organization, Geneva, Switzerland.
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Results
We enrolled 400 eligible children and 400/400 (100%) completed the study. There was no 
drop-out because enrolment and the blood collection occurred on the same day. All collected 
blood samples were of sufficient quantity and were properly managed and analysed.
The female-to-male ratio in the sample was 1:1.3 and there were more families living with 
average monthly income of USD <75 in Killinochi than in Badulla or Colombo. The 
vaccination history with OPV was >90% in all areas and for all age groups (Table 1).
There were no significant differences in the serological results between the three districts 
(data not shown). The seroprevalence to all three serotypes was above 90% for the 9–11 
months and 3–4 years age groups. For the 7–9 years and 15 years age groups, the proportion 
of seropositive children for poliovirus types 1 and 2 remained above 90%, but for serotype 3 
it dropped to 77% for 7–9-year olds and to 75% in 15-year olds. (Table 1, Figure 1) The 
median titers were high for all three serotypes in the youngest age groups and decreased 
with increasing age (Table 1, Figure 1). No children were found to be seronegative to all 
three poliovirus types but there were 7/400 (1.8%) children seronegative for 2 of the 3 
serotypes.
Discussion
In our study we observed high serological protection against polioviruses in all age groups 
and for all three serotypes. The Sri Lankan immunization program has achieved a high level 
of population immunity through its routine immunization program and without polio 
supplementary immunization activities. Our study purposefully selected areas with a higher 
proportion of children from lower socio-economic strata to specifically address the 
population assumed to be at highest risk; we therefore hypothesize that seroprevalence in 
other populations of Sri Lanka would likely be equal or higher than our findings.
We observed declining seroprevalence of poliovirus type 3 neutralizing antibodies in the 
older age groups, while seroprevalence against poliovirus types 1 and 2 remained unchanged 
with age. Further, as expected, the median titer of poliovirus neutralizing antibodies declined 
for all three serotypes with interval from last vaccination, which in this study, corresponds 
with increasing age [9, 10]. This decline, including to non-detectable titers (i.e., <1:8) for 
some subjects, does not imply loss of protection against paralytic disease, as demonstrated 
by rapid anamnestic responses following re-vaccination in older adults [11, 12]. However, 
because of rapidly waning mucosal immunity, these individuals would likely excrete 
polioviruses in stool and therefore participate in the chain of transmission if exposed to live 
polioviruses [13].
This study had some limitations. Selection of subjects was based on the knowledge of the 
area Public Health Midwife and available field-level registers kept with the Medical Officers 
of Health. This may have resulted in exclusion of some households because they were not 
included in the registers. However, the Sri Lankan health system provides registration of all 
births. In Sri Lanka, very few children are unregistered with the Medical Officers and 
therefore we believe that this bias was unimportant.
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Sri Lanka is well positioned to implement the changes to its immunization program 
recommended by the Strategic Advisory Group of Experts of the WHO – the introduction of 
one dose of IPV and the switch from tOPV to bOPV. Our results provide important baseline 
data prior to the switch; repeating similar survey after the switch will allow assessment of 
population immunity to polioviruses achieved with the new polio immunization schedule.
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Figure 1. 
Seroprevalence and reciprocal antibody titers in the selected age groups [with 95% CI]
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Table 1:
Baseline characteristics and serological results
9–11 months 3–4 years 7–9 years 15 years Total
BASELINE CHARACTERISTICS
Enrolled 100 100 100 100 400
Colombo 37 34 33 33 137
Badulla 30 32 33 34 129
Killinochi 33 34 34 33 134
      
Gender (% Female)
Colombo 54% 41% 39% 33% 42%
Badulla 37% 47% 52% 44% 45%
Killinochi 36% 44% 41% 42% 41%
      
Fully Vaccinated with OPV (%)
Colombo 100% 100% 100% 100% 100%
Badulla 97% 100% 100% 100% 99%
Killinochi 100% 100% 100% 91% 98%
      
Average Monthly Income per Household < $ 75 (%)
Colombo 0% 0% 3% 0% 1%
Badulla 3% 0% 9% 6% 5%
Killinochi 36% 18% 0% 9% 16%
SEROLOGICAL RESULTS
Poliovirus Type 1
% positive (95% CI) 96 (90.1, 98.9) 99 (94.6, 100) 99 (94.6, 100) 97 (91.5, 99.4) 98 (95.6, 98.9)
Median Titer, (95% CI) ≥1448 (≥1448, ≥1448) 724.1 (455, 1152) 325 (181, 455) 90.5 (56, 144) 455 (455, 724)
      
Poliovirus Type 2
% positive (95% CI) 98 (93, 99.8) 97 (91.5, 99.4) 99 (94.6, 100) 100 (96.4,100) 99 (96.6, 99.4)
Median Titer, (95% CI) ≥1448 (≥1448, ≥1448) 576 (408, 724) 227 (144, 455) 113 (90, 181) 455 (362, 576)
      
Poliovirus Type 3
% positive (95% CI) 95 (88.7, 98.4) 90 (82.4, 95.1) 77 (67.5, 84.8) 75 (65.3, 83.1) 84 (80.3, 87.7)
Median Titer, (95% CI) 910 (576, 1152) 113 (64, 227) 36 (18, 90) 28 (11, 45) 91 (72, 144)
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